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Activation function 2 in the ligand binding domain of
nuclear receptors forms a hydrophobic cleft that binds
the LXXLL motif of p160 transcriptional coactivators.
Here we provide evidence that activation function 2 in
the androgen receptor serves as the contact site for the
androgen dependent NH2- and carboxyl-terminal inter-
action of the androgen receptor and only weakly inter-
acts with p160 coactivators in an LXXLL-dependent
manner. Mutagenesis studies indicate that it is the NH2-/
carboxyl-terminal interaction that is required by activa-
tion function 2 to stabilize helix 12 and slow androgen
dissociation critical for androgen receptor activity in
vivo. The androgen receptor recruits p160 coactivators
through its NH2-terminal and DNA binding domains in
an LXXLL motif-independent manner. The results sug-
gest a novel function for activation function 2 and a
unique mechanism of nuclear receptor transactivation.
Steroid receptors interact with coactivators during the re-
cruitment of active transcription initiation complexes required
for hormone-regulated gene transcription (1). Transcriptional
activation domains in the steroid receptors that may mediate
these interactions include activation function 1 in the NH2-
terminal domain and activation function 2 (AF2)1 in the ligand
binding domain (LBD). Recent studies have focused on a family
of p160 coactivators that interact with the AF2 region that
include steroid receptor coactivator 1 (SRC1) (2) and the hu-
man transcriptional intermediary factor 2 (TIF2) (3). SRC1 and
TIF2 contain distinct nuclear receptor interaction domains in
the central and/or carboxyl-terminal regions (3, 4). Mutagene-
sis studies demonstrated a functional link between AF2 activ-
ity in the LBD and the binding of p160 coactivators (5, 6). The
p160 coactivators interact with the AF2 hydrophobic surface of
the LBD through conserved LXXLL motifs that form am-
phipathic a helices (7, 8). Recent co-crystal structures of nu-
clear receptor LBDs and LXXLL motif fragments confirm that
AF2 recruits TIF2 and SRC1 through their LXXLL motifs (6,
9–11). A multistep mechanism for transcriptional activation by
nuclear receptors involves hormone-dependent recruitment
and association through these LXXLL binding motifs of histone
acetyltransferase activity associated with the p160 coactivator
family, CREB-binding protein/p300, and p300/CREB-binding
protein-associated factor, resulting in chromatin remodeling
(12, 13) and the formation of a transcriptionally competent
Srb/mediator coactivator complex (thyroid hormone receptor-
associated protein/vitamin D receptor-interacting protein) com-
plex (14).
However, androgen receptor (AR) AF2 activity is not de-
tected in a variety of mammalian cell lines (15–18) despite
homology of the region with other nuclear receptors. We there-
fore investigated the mechanism whereby AR recruits p160
coactivators and the role of AF2 in AR function. It is demon-
strated that weak interactions between the AR LBD and SRC1
and TIF2 correspond with weak AR AF2 activity. The AF2
surface in the AR LBD instead functions as a strong interaction
site for the AR NH2-terminal domain that is required for AR
activity in vivo. SRC1 and TIF2 interact with the AR NH2-
terminal and DNA binding domain (DBD) regions in an LXXLL
motif-independent manner mediated by the carboxyl-terminal
region of SRC1 and the carboxyl-terminal and central regions
of TIF2.
EXPERIMENTAL PROCEDURES
Construction of Plasmids—TIF2 constructs were as described previ-
ously (3). pCR3.1SRC1a was provided by Ming-Jer Tsai and Bert
O’Malley (2, 19). The GALSRC1 constructs were prepared as follows:
GALSRC1–1441 by using the pCR3.1hSRC1a BspHI(blunt)/XbaI frag-
ment cloned into pGALO (SmaI/XbaI); GALSRC1–780 by digesting
GALSRC1–1441with BamHI/XbaI and religating; GALSRC568–1441
by cloning the EcoRI(blunt)/XbaI pCR3.1hSRC1a fragment into pGALO
(SalI(blunt)/XbaI); GALSRC564–800 and GALSRC564–1138 using the
polymerase chain reaction (PCR) amplification using 59-NdeI and 39-
XbaI primers and the fragment cloned into pGALO (NdeI/XbaI);
GALSRC568–954 by digesting GALSRC568–1441 with SacI/XbaI and
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religating; GALSRC1139–1441 by cloning the HindIII(blunt)/
XbaI pCR3.1hSRC1a fragment into pGALO (SalI(blunt)/XbaI);
GALSRC1139 –1437 by cloning the PCR-amplified fragment of
pCR3.1hSRC1a using 59-BamHI and 39-XbaI primers into pGALO
(BamHI/XbaI). VPAR (human AR residues 1–919) and VPAR1–660 (AR
NH2-terminal and DBD residues 1–660) contained the VP16 transac-
tivation domain (16, 20). VPSRC1 constructs were created as follows:
VPSRC1–1441 by excising full-length SRC1a from pCR3.1hSRC1a us-
ing BspHI (blunt)/XbaI and cloned into pNLVP16 (XhoI(blunt)/XbaI);
VPSRC568–1441 by cloning the EcoRI(blunt)/XbaI pCR3.1hSRC1a
fragment into pNLVP16 (SalI(blunt)/XbaI). VPSRC564–800 by ampli-
fication of pCR3.1hSRC1a using a 59 NdeI and 39 XbaI primers into
pNLVP16 (NdeI/XbaI); VPSRC1139–1441 by cloning the HindII-
I(blunt)/XbaI fragment of pCR3.1hSRC1a into pNLVP16 (SalI (blunt)/
XbaI). Single base mutations in the AR LBD were created by PCR
mutagenesis, and all constructs were verified by DNA sequencing.
Mammalian Two Hybrid Assay—The NH2-terminal and carboxyl-
terminal (N/C) interaction assay between the AR NH2- and carboxyl-
terminal regions was determined using GALAR624–919, a fusion pro-
tein with Saccharomyces cerevisiae GAL4 DBD residues 1–147 and AR
LBD residues 624–919 in pGALO (16, 20) with VPAR1–660 (AR NH2-
terminal and DBD residues 1–660) containing the herpes simplex virus
VP16 transactivation domain residues 411–456 (16, 20). CHO cells
were transfected using DEAE-dextran (16, 20) with 1 mg of GAL and
VP16 fusion vectors and 5 mg of G5E1b-luciferase reporter. Activity was
determined as indicated or in the presence or absence of 1 mM dihy-
drotestosterone (DHT). Fold induction relative to the no hormone con-
trol is indicated above the bars. For interactions between TIF2 and
SRC1, GALAR624–919 was cotransfected with VPTIF2 or VPSRC1
fusion constructs in the CHO two hybrid assay. VPAR and VPAR1–660
were expressed with GALTIF2 or GALSRC1 mutants containing the
GAL4 DBD. Control interactions were with pNLVP16 (VP16).
In Vitro Binding Assays—GST fusion proteins were expressed in
XL1-Blue Escherichia coli cells treated with 0.5 mM isopropyl-1-thio-b-
D-galactopyranoside for 3 h after log phase growth. Bacteria were son-
icated and centrifuged, and the supernatant was incubated with gluta-
thione-agarose beads (Amersham Pharmacia Biotech) for 1 h at 4 °C.
Beads are washed five times with 0.5% Nonidet P-40, 1 mM EDTA, 0.1
M NaCl, 0.02 M Tris-HCl, pH 8.0, and incubated for 2 h at 4 °C with and
without 0.2 mM DHT, and in vitro translated proteins were labeled with
25 mCi of [35S]methionine (NEN Life Science Products) using the TNT
T7 quick coupled transcription/translation system (Promega) in the
presence and absence of 0.2 mM DHT. Beads were centrifuged, washed
five times, and boiled in SDS. Input lanes contain approximately 20%
that used for the binding reactions. GSTAR1–660 was prepared by
excising AR1–660 coding for AR NH2-terminal and DBD residues
1–660 from GALAR using TthIII(blunt)/BamHI and cloned into pGEX-
5X-1 (Amersham Pharmacia Biotech) at SmaI/BamHI. GSTTIF2M
(TIF2 624–1141) and GSTTIF2C (TIF2 1144–1464) were PCR ampli-
fied, and fragments were cloned in pGEX-2T (EcoRI/BamHI). TIF2
carboxyl-terminal residues 1143–1464 were amplified from pSG5TIF2
by PCR and cloned into pcDNA3HA (provided by Yue Xiong) at the
BamHI/XbaI sites to prepare 35S-labeled TIF2-C. pGEMhAR (provided
by Jiann-an Tan and Frank S. French) coded for full-length human AR
residues 1–919 and was used to prepare 35S-AR. GSTAR1–565 was
prepared by digesting GALAR1–919 with HindIII(blunt)/BamHI and
cloned into pGEX-3X at EcoRI(blunt)/BamHI. pcDNA3HA-AR-LBD ex-
pressing the human AR LBD residues 624–919 was digested from
GALAR624–919 with BamHI/XbaI and cloned in the same sites in
pcDNA3HA for in vitro translation.
RESULTS AND DISCUSSION
Expression of the AR DBD and LBD fragment AR507–919
(Fig. 1A) or AR LBD residues 624–919 fused with the GAL4
DBD (GALAR624–919, Fig. 1B) shows little or no induction of
transcriptional activity indicating the absence of AF2 activity.
In contrast, agonist-dependent AF2 activity of the GAL4-glu-
cocorticoid or estrogen receptors LBD fusion proteins were
16 6 6-fold and 3.6 6 0.3-fold (Fig. 1B). Lack of AF2 activity by
the AR LBD might result from failure to recruit p160 coacti-
vators. Moreover, in transient cotransfection assays, expres-
sion of SRC1 or TIF2 increased full-length AR transcriptional
activity about 3–6-fold, which surprisingly was only partially
diminished by mutation of the three LXXLL motifs in TIF2
(TIF2 m123, Fig. 1A) and SRC1 (21), suggesting that p160
coactivators can increase AR transactivation in an LXXLL
motif-independent manner. We therefore investigated the in-
teraction of AR with SRC1 and TIF2.
Of several fragments tested in a mammalian two hybrid
assay, only TIF624–1287 and SRC568–1441 each with three
(3) and four LXXLL motifs, respectively, interacted 2–3-fold
with the AR LBD (GAL-AR624–919, Fig. 2), which was less
than 10% the activity observed in the N/C interaction (see
below and Fig. 4A), suggesting weak coactivator binding affin-
ity compared with the interaction between the NH2- and car-
boxyl-terminal AR domains. Although results are shown at
FIG. 1. Transcriptional activation by AR. A, effect of overexpres-
sion of p160 coactivators. The expression vector pCMVhAR507–919
coding for the AR DBD and LBD (AR507–919, 50 ng) was cotransfected
without or with 2 mg of pSG5TIF2 or pSG5TIF2 m123 and 5 mg of mouse
mammary tumor virus (MMTV) luciferase reporter. Full-length human
AR expression vector pCMVhAR (AR, 20 ng) was cotransfected without
or with 6 mg of pSG5SRC1, pSG5TIF2, or pSG5TIF2 m123 together
with 5 mg of the MMTV luciferase reporter. The parent vector pCMV5
(p5, 50 ng) was cotransfected with 5 mg of the luciferase reporter.
Monkey kidney CV-1 cells were transfected using calcium phosphate
(34). The last two leucine residues in each of three LXXLL motifs were
mutated to alanine in pSG5TIF2 m123 (3). B, transcriptional activity of
AR, glucocorticoid receptor (GR), and estrogen receptor (ER) LBDs
expressed as fusion proteins with the GAL4 DBD. CHO cells were
cotransfected with 1 mg of pNLVP16 parent vector (VP16) together with
1 mg of GALAR624–919, GALGR486–778, or GALER250–595, and 5 mg
of G5E1b-luciferase reporter (16, 20). Cells were incubated 24 h with or
without 1 mM DHT, dexamethasone, or 17b-estradiol with the cognate
receptor fragment.
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saturating DHT concentrations (1 mM, Fig. 2, Table I), interac-
tions between the p160 coactivators and the AR LBD in the two
hybrid assay were detected at 0.01 nM DHT. The LBD regions
of the glucocorticoid (486–778) and estrogen (250–595) recep-
tors interacted with these fragments 69 6 4-fold and 5.9 6
1.2-fold, and 7.5 6 1.7 and 8.2 6 1.7, respectively (data not
shown). However, overexpressed TIF2, but not a mutant with
three mutated LXXLL motifs, increased activation by the AR
LBD (AR507–919, Fig. 1A), indicating that exogenously ex-
pressed coactivators can rescue LXXLL motif-dependent AF2
activity in the AR LBD, which as shown below was blocked by
site-directed mutations in AF2 (see Fig. 4B). The results sug-
gest that the apparent lack of AR AF2 activity results from
inefficient LXXLL motif-dependent recruitment of endogenous
coactivators. Recovery of AF2 by overexpression of p160 coac-
tivators suggests overall retention of nuclear receptor AF2
TABLE I
Summary of AR LBD mutants
Apparent equilibrium binding affinity and dissociation half-times were determined in COS cells at 37 °C using wild-type or mutant pCMVhAR
full-length AR or AR507–919 coding for the DBD and LBD (20, 33). DHT concentration for at least 10-fold transcriptional activity (MMTV-Luc)
was determined in CV-1 cells using pCMVhAR full-length wild-type and mutant. TIF2 two hybrid interaction was determined using VPTIF624–
1287 and GALAR624–919 with wild-type or mutant sequence in CHO cells at 1 mM DHT, shown as fold induction relative to activity determined
in the absence of hormone. The AR-TIF2 interaction was also determined by cotransfecting pCMVhAR507–919 and pSG5TIF2 with the
MMTV-luciferase reporter in CV-1 cells assayed at 10 nM DHT. The N/C interaction (16, 20) shows the DHT concentration for at least 3-fold
induction using VPAR1–660 and GALAR624–919 with wild-type or mutant sequence determined in CHO cells. The N/C interaction was also
determined by cotransfecting pCMVhAR1–660 and pCMVhAR1–503 and MMTV-Luc in CV-1 cells at 10 nM DHT. Androgen insensitivity
syndrome (AIS) stage is on a scale where 1 is normal and 7 is complete (44). AF2, helix, and loop regions were based on crystal structures of estrogen
and progesterone receptor LBDs (29, 30). Signature sequence is amino acid residues 718–741 in human AR (31). PC indicates somatic prostate
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nM min nM DHT nM DHT
Wild-type 0.48 6 0.25 149 6 32 44 6 4 0.001 2.1 6 0.5 11 0.1 11 1
AF2 domain
V716R 0.40 6 0.04 28 6 3 20 6 2 0.1 1.0 6 0 2 2 2 3
K720A 0.54 6 0.15 134 6 11 26 6 4 0.001 1.2 6 0.2 1 1 11 K720E, PC 3
I737T 0.44 6 0.20 147 6 38 42 6 2 0.1 1.1 6 0.04 1 100 11 3 4
E897K 0.52 6 0.18 67 6 11 38 6 2 1 1.0 6 0 2 2 2 12
I898T 0.34 6 0.02 42 6 5 7 6 1 0.1 1.7 6 0.2 11 2 1 6,7 12
Signature sequence
L722A 0.58 6 0.13 102 6 24 nd 1 1.9 6 0.2 nd 10 L722F, 6–7 3-4 loop
F725L 0.82 6 0.32 127 6 39 38 6 5 0.1 1.2 6 0.1 11 100 11 3,4 3-4 loop
L728A 0.56 6 0.17 82 6 9 nd 0.1 1.4 6 0.03 nd 100 nd L728S, 3–5 3-4 loop
Y739A 0.65 6 0.16 34 6 3 8 6 1 0.1 2.7 6 0.4 11 10 11 Y739R, 6–7 4
W741A 0.67 6 0.31 33 6 5 7 6 1 0.1 1.9 6 0.4 11 100 1 W741R, 6–7 5
Other domains
H729A 0.70 6 0.30 132 6 32 nd 0.01 3.3 6 1.0 nd 0.1 nd 3-4 loop
A735T/V736L 0.42 6 0.02 216 6 56 47 6 6 0.001 2.7 6 0.5 11 0.1 11 4
Q798A 0.48 6 0.19 148 6 27 37 6 5 0.001 1.2 6 0.3 11 0.1 11 Q798E, 5 7–8 loop
Q867H/P868D 0.52 6 0.19 272 6 57 50 6 7 0.001 2.9 6 0.6 11 0.1 11 11-12 loop
V889M 0.46 6 0.25 18 6 2 3 6 0 1 1.5 6 0.3 11 100 1 7 11-12 loop
FIG. 2. Two hybrid interaction of
TIF2 and SCR1 fragments with the
AR LBD and NH2-terminal fragments
that include the AR DNA binding do-
main. The TIF2 and SRC1 fragment
(amino acid residue boundaries indicated)
expression vectors prepared as described
under “Experimental Procedures” were
cotransfected with GALAR624–919 ex-
pressing the AR DBD and LBD, the VP16-
full-length AR fusion protein (VPAR), or
the AR NH2-terminal region and DBD
(VPAR1–660). Indicated is the mean fold
induction 6 standard error of at least
three independent experiments. nd, not
determined; 2, not detectable; bHLH, ba-
sic helix-loop-helix motif; PAS, Per-Arnt-
Sim homology region; NID, nuclear recep-
tor interaction domain; AD, activation
domain.
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structure (6, 22, 23).
The role of the AR NH2-terminal and DBD regions in p160
coactivator recruitment was also investigated using the two
hybrid assay. A 2–5-fold interaction between TIF624–1179 or
TIF1288–1464 with full-length AR (VPAR, Fig. 2A) or the
constitutively active NH2-terminal and DBD fragment AR1–
660 (VPAR1–660, Fig. 2A) indicates interaction of AR with two
regions of TIF2. This interaction increases to 7–14-fold by
including the TIF2 glutamine-rich region in TIF624–1287 and
TIF1143–1464 (Fig. 2A). The results of GST adsorption assays
confirm that both the central and carboxyl-terminal domains of
TIF2 interact with the AR NH2-terminal and DBD fragment
(Fig. 3A). Deletion mapping of SRC1 indicates that mainly its
carboxyl-terminal region interacts with AR or the AR NH2-
terminal fragment, and deletion of the SRC1 carboxyl-terminal
LXXLL motif did not diminish this interaction (Fig. 2B). Dele-
tions of AR NH2-terminal residues 339–499, but not D14–150
or D142–337, decreased the SRC1 interaction by 50% suggest-
ing this region of the NH2 terminus contributes to the LXXLL-
independent interaction with TIF2 and SRC1 (data not shown).
We concluded that AR can recruit p160 coactivators through its
NH2-terminal and DBD regions independent of the LXXLL
motifs by interacting with the carboxyl-terminal region of
SRC1 or the carboxyl and central regions of TIF2. Whereas the
role of nuclear receptor NH2-terminal domains in recruiting
160 coactivators has been controversial (4, 24–28), this inter-
action clearly contributes to the LXXLL motif-independent ac-
tivation of AR.
The function of the AF2 region in AR-mediated gene activa-
tion was further investigated by site-directed mutagenesis.
Sequence alignments based on steroid receptor LBD crystal
structure predictions (29–31) place several androgen insensi-
tive and site-directed mutations within AF2 helices 3, 4, and 12
and a highly conserved nuclear receptor signature sequence
(31). Sites for mutagenesis were based on an association with
the androgen insensitivity syndrome and with retention of high
affinity androgen binding (Table I). All of the AR LBD mutants
expressed at similar levels based on binding capacity and re-
tained high affinity binding of the synthetic androgen
[3H]R1881 (Kd 0.3–0.7 nM) (Table I) indicating conservation of
the ligand binding pocket. However, mutations at V889M,
Y739A, W741A, E897K, I898T, and V716R increased the dis-
sociation rate of androgen bound to full-length AR by 2–5-fold
(Table I) suggesting an increased association rate and pertur-
bation of the hormone binding region. V889M lies between
helices 11 and 12 and causes nearly complete androgen insen-
sitivity (32), increases the androgen dissociation rate (33), and
interferes with the androgen-dependent interaction between
the AR NH2- and carboxyl-terminal regions (16, 20). The N/C
interaction facilitates AR transcriptional activity at physiolog-
ical androgen concentrations (34) but, unlike peroxisome pro-
liferator-activated receptor g (35), is not required for high af-
finity androgen binding (16).
When expressed in full-length AR, all AF2/signature se-
quence mutants, with the exception of K720A (see below),
required 100–1000-fold higher DHT concentrations to activate
an androgen responsive reporter (Table I) indicating greatly
reduced function by the mutant ARs. Almost all of the AF2/
signature mutants had reduced to undetectable interaction
with TIF2 (Table I), SRC1 (data not shown), and the AR NH2-
terminal domain (Table I), whereas most mutants outside this
region had wild-type activity. Transcriptional activity at 0.1–1
nM DHT in the absence of an N/C interaction for V716R and
E897K (Table I) shows that AR function can be compensated in
vitro by elevated androgen levels (34), whereas in vivo, de-
creased N/C interaction is associated with partial (I737T,
F725L) or complete (I898T, V889M) androgen insensitivity
(Fig. 4A). Transcriptional activity of the AR DBD/LBD frag-
ment AR507–919 coexpressed with TIF2 or with the AR NH2-
terminal fragment AR1–503 lacking the AR DBD was also
decreased by several of the mutations (Fig. 4B, Table I). Thus
many of the same residues in the AF2/signature sequence serve
as both a weak binding site for p160 coactivators and for the AR
NH2-terminal domain. However, the binding sites are not iden-
tical, because AR mutant I898T greatly decreased the N/C
interaction but retained strong p160 coactivator binding, and
K720A retained the N/C interaction but essentially lost p160
coactivator binding (Fig. 4, A and B).
The functional significance of the AR AF2 region was there-
fore distinguished by these mutations, K720A and I898T. Lys-
720 lies within helix 3 of the AF2 hydrophobic surface in a
region highly conserved among nuclear receptors. Lys-720 cor-
responds to Lys-366 in mouse estrogen receptor, whose muta-
tion eliminates estrogen receptor transcriptional activity (22),
and to Lys-301 in peroxisome proliferator-activated receptor g,
where it forms part of an LXXLL motif charge clamp (9). K720A
retains the transcriptional activity of wild-type AR (Table I)
(36), even though the p160 coactivator binding by the LBD is
low to undetectable (Fig. 4, A and B, Table I). Retention of
wild-type AR transcriptional activity by K720A correlates with
the 21-fold N/C interaction (Fig. 4A), but not with the LXXLL
motif-dependent p160 coactivator recruitment by the AR LBD
(Fig. 4, A and B). An AR somatic mutation at this same site
(K720E) in a bone metastases of hormone refractory prostate
cancer also retained a normal transcriptional response (37, 38)
typical of most prostate cancer AR mutations (39). A mutation
at the corresponding Lys-366 in the estrogen receptor distin-
guished the binding of SRC1 and RIP140, coactivators that
interact through LXXLL motifs at the same hydrophobic cleft
FIG. 3. In vitro interactions between AR, AR fragments, and
TIF2 by GST adsorption. GST adsorption experiments were per-
formed as described under “Experimental Procedures.” A, the in vitro
translated 35S-labeled carboxyl-terminal TIF2-C fragment (amino acid
residues 1143–1464), the AR NH2-terminal region and DBD (
35S-AR1–
660), and full-length AR (35S-AR) were incubated with GST or the
indicated GST fusion resins including GST-AR NH2-terminal region
and DBD (GST-AR1–660), the central TIF2 fragment GSTTIF2M (ami-
no acid residues 624–1141), and the carboxyl-terminal TIF2 fragment
GSTTIF2-C (residues 1143–1464). B, 35S-AR-LBD (624–919) coding for
LBD residues 624–919 was reacted with GST or GST fusion protein
resins containing the AR NH2-terminal region (GST-AR1–565), the AR
NH2-terminal region, and DBD (GST-AR1–660) or GSTTIF2M. Incu-
bations were performed in the presence and absence of 0.2 mM DHT.
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(22), suggesting this residue contributes to multiple overlap-
ping interaction sites. I898T, on the other hand, retains strong
coactivator binding to AF2 but has a greatly reduced N/C
interaction (Fig. 4, A and B) and is associated with complete
androgen insensitivity (Table I). Thus a decline in the N/C
interaction at AF2, but to a much less extent coactivator inter-
action at AF2, is associated with androgen insensitivity and
thus loss of AR function in vivo.
Although p160 coactivators may contribute to the N/C inter-
action (4, 40, 41), several lines of evidence, including recent
studies with the progesterone receptor (42), support a direct
N/C interaction. 1) In our studies, overexpression of TIF2 or
SRC1 has no effect on the AR N/C interaction in the mamma-
lian two hybrid assay (data not shown). 2) The AR N/C inter-
action is detected in both mammalian and yeast two hybrid
assays. 3) AR GST adsorption experiments where the GST-AR
LBD fusion protein interacts in an androgen-dependent man-
ner with the AR NH2-terminal domain (Fig. 3B) are consistent
with a direct N/C interaction. 4) The N/C interaction site in the
AR LBD overlaps, but is not identical to, the p160 coactivator
LXXLL motif binding site. 5) The AR LBD appears to bind the
NH2-terminal domain with higher affinity than it does the
LXXLL motif. The data predict that AF2 mutations that dis-
rupt p160 coactivator binding alter male phenotypic expression
only if they interfere with the overlapping N/C interaction site.
Most AF2 and signature sequence mutations that increase
the androgen dissociation rate and cause severe androgen in-
sensitivity (Table I) (43) are associated with helix 12 (29).
Androgen dissociation rates from the DBD/LBD AR507–919
fragment increased 7-fold from t1⁄2 44 min to t1⁄2 3–8 min at
37 °C by W741A, I898T, Y739A, and V889M (Table I). Trp-741
in helix 5 is predicted to contact Ile-898 in helix 12, Tyr-739 in
helix 4 contacts Val-911 in helix 12, and Val-889 lies between
helices 11 and 12 (Fig. 5). Trp-741 corresponds to Trp-755 in
the progesterone receptor, which directly interacts with bound
agonist (29), so a mutation at this site could directly increase
FIG. 4. AR mutations that distin-
guish coactivator binding and the
N/C interaction. A, two hybrid interac-
tion assay between the AR LBD mutants
and the AR NH2-terminal domain, TIF2
and SRC1. GALAR624–919 coding for the
AR LBD residues 624–919 with wild-type
sequence (WT) or the indicated mutations
were tested in the CHO cell two hybrid
assay as described under “Experimental
Procedures” using pNLVP16 (VP16),
VPAR1–660 (AD) coding for the NH2-ter-
minal region and DBD, or the VP16 fu-
sion proteins with full-length SRC1 (SRC)
and TIF2 (TIF). The experiment shown is
representative of at least three independ-
ent experiments where fold induction is
shown above the bars. B, transcriptional
activation by the AR LBD in the presence
of TIF2 and the AR NH2-terminal region.
Transient cotransfection experiments
were performed in CV-1 cells using the
MMTV-luciferase reporter vector as de-
scribed under “Experimental Procedures”
in the absence (2) or presence (1) of 10
nM DHT. AR507–919 with wild-type (WT)
or mutant sequence as indicated were co-
expressed with 0.5, 2, and 6 mg of pSG5-
TIF2 or 0.1, 0.5, or 1 mg of pCMVhAR1–
503 coding for the AR NH2-terminal
region but lacking the AR DBD. The ex-
periment shown is representative of at
least three experiments, and the fold in-
duction is shown above the bars.
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the ligand dissociation rate. On the other hand, I737T in helix
4 and F725L between helices 3 and 4 cause only partial andro-
gen insensitivity (44) and are not predicted to contact helix 12.
Nor do they influence the androgen dissociation rate or com-
pletely disrupt the N/C interaction (Table I). These and other
mutations not associated with helix 12 (V716R, K720A, Q867H/
P868D) retained the wild-type androgen dissociation rate.
Thus helix 12 appears to stabilize androgen in the binding
pocket.
The N/C interaction appears to further stabilize helix 12 and
bound androgen. As we showed previously, deletion of the
NH2-terminal domain increases the androgen dissociation rate
by 4–5-fold (20, 33). Furthermore, E897K in helix 12 elimi-
nates the N/C interaction and increases the androgen dissoci-
ation rate 2-fold (Table I). Glu-897 is equivalent to Glu-471 in
helix 12 in peroxisome proliferator-activated receptor g, which
forms part of the LXXLL charge clamp of AF2 (9), supporting
overlapping coactivator and AR NH2-terminal binding sites.
V716R, though not positioned near helix 12, eliminates the N/C
interaction, and the androgen dissociation rate increased 5-fold
(Table I). Mutations at Gln-867 and Pro-868 in the loop be-
tween helices 10–11 to the conserved residues HD of the pro-
gesterone and estrogen receptors (Q867H/P868D, Table I),
where Gln-867 juxtaposes Tyr-915 in helix 12, increased the
N/C interaction 2-fold (data not shown) and slowed the andro-
gen dissociation rate to a similar extent (Table I).
Thus the N/C interaction and the AF2/signature sequence
residues appear to contribute to the positioning of helix 12,
which results in slowing the dissociation rate of bound andro-
gen. SRC1 slowed estrogen receptor ligand dissociation (45);
however, overexpression of TIF2 had no effect on androgen
dissociation from full-length AR (data not shown). The data are
consistent with overlapping LBD AF2 binding sites for TIF2
and the AR NH2-terminal domain, which in the presence of
androgen agonist participates in the N/C interaction. For the
AR, p160 coactivator recruitment appears to be mediated pri-
marily by the AR NH2-terminal and DBD regions. As illus-
trated in Fig. 5, the data suggest that AF2 in the AR LBD
serves predominantly as an N/C interaction site, which upon
agonist binding contributes to stabilization of helix 12 to slow
androgen dissociation necessary for AR functional activity at
physiological androgen concentrations.
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